, Tracking Stock Market Picks
Enter Symbol:
Cytrx Corporation (CYTR) [hlAlert]

down 91.85 %

Cytrx Corporation (CYTR) rated Buy with price target $6.50 by Broadpoint Capital

Posted on: Wednesday,  Jan 23, 2008  8:25 AM ET by Broadpoint Capital

Broadpoint Capital rated Buy Cytrx Corporation (NASDAQ: CYTR) on 01/23/2008. Previously Broadpoint Capital rated Buy Cytrx Corporation (NASDAQ: CYTR) on 10/24/2007.,
when the stock price was $28.49. Since then, Cytrx Corporation has lost 91.86% as of 01/26/2016's recent price of $2.32.
If you would have followed the previous Broadpoint Capital's recommendation on CYTR, you would have lost 91.85% of your investment in 3016 days.

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

Broadpoint Capital, Inc. is an investment banking and capital markets firm that provides corporate and public finance services and trading of corporate, government, and municipal securities for institutions. The company has three divisions: Municipal Capital Markets division, which underwrites and trades municipal securities in new issue and secondary markets; Taxable Fixed Income division, which is a dealer focusing on fixed income securities with limited liquidity; and Equity Capital Markets division, which is a sector-focused investment banking group providing research, trading, raising of capital and advisory services for institutional and corporate clients. Broadpoint Capital, formerly known as First Albany Corporation, was founded in 1953 and is based in New York, New York. The company operates as a subsidiary of First Albany Companies Inc.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/23/2008 8:25 AM Buy
12.81 45.50
as of 12/24/2008
1 Week down  -9.75 %
1 Month up  12.12 %
3 Months up  54.16 %
1 YTD up  23.33 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2007 9:25 AM Buy
28.49 56.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy